Presentations

Presentations

Jun 11, 2023

EHA 2023 (Exa-cel)

Apr 27, 2023

2023 Proxy Statement

Apr 27, 2023

2022 Consolidated Audit Report

Apr 27, 2023

2022 Annual Report

Apr 27, 2023

2022 Compensation Report

Apr 27, 2023

2022 Statutory Financial Statements

Apr 18, 2023

EBMT 2023 Oral Presentation

Apr 17, 2023

AACR 2023 Oral Presentation

Apr 13, 2023

4/13/23 Release

Mar 30, 2023

2022 PFIC Annual Information Statement

Mar 14, 2023

3/14/23 Release

Feb 27, 2023

2/27/23 Release

Feb 21, 2023

2/21/23 Q4 Earnings Release

Feb 08, 2023

Jan 11, 2023

1/11/23 Release

Jan 09, 2023

CRISPR Therapeutics Q1 2023 Corporate Presentation

Dec 19, 2022

12/19/22 Release

Dec 12, 2022

ASH 2022 (CARBON)

Dec 12, 2022

12/12/22 Release

Dec 10, 2022

12/10/22 Release

Dec 10, 2022

ASH 2022 (Exa-cel)

Dec 01, 2022

CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference

Nov 10, 2022

SITC 2022 Oral Presentation

Nov 10, 2022

SITC 2022 Poster Presentation

Nov 01, 2022

11/1/22 Release

Oct 27, 2022

Oct 05, 2022

Sep 29, 2022

Sep 27, 2022

9/27/22 Release

Sep 06, 2022

8/31/2022 Press Release

Aug 08, 2022

Jun 21, 2022

Innovation Day Presentation

Jun 12, 2022

EHA 2022 (Exa-cel)

Jun 11, 2022

Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress

Jun 11, 2022

Jun 11, 2022

2022 EHA Oral Presentation (CTX130 COLBALT-LYM)

Jun 02, 2022

Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress

May 31, 2022

CRISPR Therapeutics to Host Innovation Day on June 21, 2022

May 16, 2022

CRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer

May 12, 2022

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

May 09, 2022

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

May 05, 2022

2021 Annual Report

May 04, 2022

CRISPR Therapeutics to Present at the 2022 Bank of America Healthcare Conference

Apr 27, 2022

2022 Proxy Statement

Apr 21, 2022

2020 Annual Report

Apr 20, 2022

2021 Consolidated Audit Report

Apr 20, 2022

2021 Statutory Financial Statements

Apr 20, 2022

2021 Compensation Report

Apr 12, 2022

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Apr 11, 2022

2022 AACR Annual Meeting

Apr 07, 2022

2022 CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Mar 22, 2022

2021 PFIC Annual Information Statement

Mar 08, 2022

CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research

Feb 28, 2022

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Feb 15, 2022

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Feb 09, 2022

CRISPR Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

Feb 02, 2022

CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)

Nov 23, 2021

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Nov 22, 2021

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies

Nov 16, 2021

CRISPR Therapeutics and ViaCyte to Start Clinical Trial of the First Gene Edited Cell Replacement

Nov 08, 2021

Nov 03, 2021

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results

Nov 02, 2021

11-02-21 Release PDF

Oct 14, 2021

10-14-21 PR Release

Oct 12, 2021

2021 Carbon PR vFinal

Oct 12, 2021

CTX110™ Virtual Event

Oct 05, 2021

CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data

Oct 01, 2021

CRISPR Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Sep 28, 2021

CRISPR Therapeutics to Participate in the Chardan’s 5th Annual Genetic Medicines Conference

Aug 05, 2021

CRISPR Therapeutics to Participate in the Canaccord Genuity 41st Annual Growth Conference

Jul 29, 2021

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results

Jun 15, 2021

CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia

Jun 11, 2021

EHA 2021 Virtual Congress (SCD)

Jun 11, 2021

EHA 2021 Virtual Congress (TDT)

May 12, 2021

Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress

May 06, 2021

CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer

Apr 29, 2021

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Apr 28, 2021

CRISPR Therapeutics Announces Trials in Progress Poster Presentation at the 2021 American Society of Clinical Oncology Annual Meeting

Apr 27, 2021

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results

Apr 26, 2021

Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia

Apr 20, 2021

Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia

Apr 10, 2021

2021 AACR Annual Meeting

Apr 10, 2021

CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function

Apr 06, 2021

CRISPR Therapeutics to Participate in the 20th Annual Needham Virtual Healthcare Conference

Mar 10, 2021

CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2021 Annual Meeting

Mar 09, 2021

2020 PFIC Annual Information Statement

Mar 04, 2021

CRISPR Therapeutics Corporate Presentation

Mar 03, 2021

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Feb 16, 2021

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Feb 05, 2021

CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day

Feb 01, 2021

CRISPR Therapeutics Announces the Appointment of Philippe Drouet as Chief Commercial Officer

Feb 01, 2021

CRISPR Therapeutics Corporate Presentation

Jan 04, 2021

CRISPR Therapeutics Corporate Presentation

Dec 14, 2020

CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV

Dec 09, 2020

Phase 1/2 CTX001™ Investor Update Presentation

Dec 06, 2020

2020 ASH Meeting and Exposition Presentation

Dec 05, 2020

CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine

Dec 01, 2020

CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ in Sickle Cell Disease and Beta Th

Nov 24, 2020

CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

Nov 16, 2020

CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference

Nov 04, 2020

CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition

Oct 21, 2020

CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies

Oct 21, 2020

Phase 1 CARBON Top-Line Data Presentation

Oct 07, 2020

CRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry

Sep 29, 2020

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Sep 22, 2020

CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease

Sep 03, 2020

CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference

Jul 30, 2020

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Jul 27, 2020

Jul 27, 2020

2019 Annual Report

Jun 30, 2020

CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares

Jun 29, 2020

CRISPR Therapeutics Announces Proposed Offering of Common Shares

Jun 25, 2020

CRISPR Therapeutics Announces the Build-Out of New Cell Therapy Manufacturing Facility

Jun 17, 2020

2020 AACR II Virtual Meeting Poster: Functional and single-cell assessment of CRISPR-modified CAR-T cells from NSCLC patients and healthy donors

Jun 16, 2020

2020 AACR II Virtual Meeting Poster: Allogeneic CAR-T cell products containing 10 gene edits using CRISPR/Cas9 can retain full functionality in vivo and in vitro

Jun 15, 2020

2020 AACR II Virtual Meeting Poster: Allogeneic anti-PTK7 CAR-T cells for the treatment of solid tumors

Jun 14, 2020

2020 AACR II Virtual Meeting Poster: Targeting T cell lymphomas with CRISPR/Cas9-generated anti-CD70 allogeneic CAR-T cells

Jun 12, 2020

2020 European Hematology Association (EHA) Congress Presentation

May 11, 2020

2020 ASGCT Annual Meeting Poster: Multiplexing of up to 10 gene edits using CRISPR/Cas9 generate CAR-T cells with improved function

May 11, 2020

2020 ASGCT Annual Meeting Poster: Dual Guide CRISPR/Cas9 Editing of the CCR5 Gene Provides Complete Protection Against HIV in Humanized Mouse Models

May 11, 2020

2020 ASGCT Annual Meeting Poster: Insertion of Short Double-Stranded Oligonucleotides Using CRISPR/Cas9 as a Therapeutic Approach for Glycogen Storage Disease Type 1a

Apr 07, 2020

2019 PFIC Annual Information Statement

Apr 02, 2020

CRISPR Therapeutics Corporate Presentation

Mar 18, 2020

CRISPR Therapeutics Corporate Presentation

Nov 19, 2019

CRISPR Therapeutics Data Update Call Presentation

Nov 08, 2019

2019 Annual Meeting of The Society for Immunotherapy of Cancer (SITC) Poster: Single-cell RNA sequencing and functional assessment of healthy donor- and cancer patient-derived T and CAR-T cells

Sep 17, 2019

2019 European Association for the Study of Diabetes (EASD) Presentation

May 01, 2019

2019 ASGCT Annual Meeting Poster: CRISPR/Cas9 Gene Editing to Produce Multiple Allogeneic CAR-T Cell Candidates Showing Consistently High Potency, Durability, Lack of Alloreactivity, and Ability to Overcome Immune Suppression

Apr 02, 2019

2019 American Association for Cancer Research (AACR) Annual Meeting Poster: Targeting multiple solid tumor types with anti-CD70 allogeneic CAR-T cells

Apr 01, 2019

2019 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic CRISPR/Cas9 Gene-edited CAR-T Cells Targeting CD33 Show Potent Preclinical Activity Against AML Cells

Dec 01, 2018

2018 Annual Meeting of The American Society of Hematology (ASH) Poster: Preclinical Development of CTX120, an Allogeneic CAR-T Cell Product Candidate Targeting BCMA

Nov 09, 2018

2018 Annual Meeting of The Society for Immunotherapy of Cancer (SITC) Poster: CRISPR/Cas9 Enables the Efficient Production of Allogeneic CAR-T Cells Engineered to Contain Multiple Genome Edits to Enhance Therapeutic T Cell Function

May 15, 2018

2018 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Poster: Allogeneic CAR-T Cells with Multiple Therapeutically Favorable Edits Can Be Created Efficiently Using CRISPR/Cas9

Apr 16, 2018

2018 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic CRISPR Engineered Anti-CD70 CAR-T Cells Demonstrate Potent Preclinical Activity Against Both Solid and Hematological Cancer Cells

Apr 16, 2018

2018 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic Chimeric Antigen Receptor T Cells Targeting B Cell Maturation Antigen

You are now leaving the CRISPR Therapeutics website.

CRISPR Therapeutics is not responsible for the content or availability of third-party sites.